Archives ms

by in
Entry Author Date Location
Biogen R&D Chief Doug Williams Leaves to Run New Cancer Startup 07/10/15 Boston
Myomo Continues Comeback, Adds $2M to Boost Robotic Arm Brace 10/09/13 Boston
Biogen’s Oral MS Drug Tops Estimates, Brings in $192M in First Quarter 07/25/13 Boston
Provid Pharma Leans on MS Society’s Venture Fund to Boost Lead Drug 04/12/12 New York
Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial 11/14/11 Boston
Acorda Stock Halted as Shares Skyrocket on Patent Speculation 04/14/11 New York
Biogen Gets Int’l Rights to Acorda’s MS Drug 07/01/09 Boston
Biogen Reports 10th PML Case in Tysabri Patient 06/29/09 Boston
FDA Allows High-Yield Tysabri Production 04/16/09 Boston
Genzyme Rises on Promising Campath Data and (or) Takeover Speculation 10/15/07 Boston
Page 1 of 1